Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study-Reference-Cited by-同舟云学术

Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study

Published:2020-11 Issue:11 Volume:2 Page:e677-e688
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Buckley Christopher D,Simón-Campos Jesus A,Zhdan Vyacheslav,Becker Brandon,Davy Katherine,Fisheleva Elena,Gupta Anubha,Hawkes Carol,Inman David,Layton Mark,Mitchell Nina,Patel Jatin,Saurigny Didier,Williamson Russell,Tak Paul P

Funder

GlaxoSmithKline foundation

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference27 articles.

1. Advances in rheumatology: new targeted therapeutics;Tak;Arthritis Res Ther,2011

2. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study;Lee;Arthritis Res Ther,2011

3. Targeting GM-CSF in inflammatory diseases;Wicks;Nat Rev Rheumatol,2016

4. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases;Hamilton;Nat Rev Drug Discov,2016

5. Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain;Cook;Ann Rheum Dis,2013

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis;Journal of Patient-Reported Outcomes;2024-01-22

2. Why does malaise/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis;Expert Review of Clinical Immunology;2024-01-19

3. An Update on the Emerging Role of Wnt/β-catenin, SYK, PI3K/AKT, and GM-CSF Signaling Pathways in Rheumatoid Arthritis;Current Drug Targets;2023-12

4. Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023;Annals of the Rheumatic Diseases;2023-10-30

5. Evaluation of the anti-arthritic activity of Capparis spinosa L. roots extracts incomplete Freund’s adjuvant-induced arthritis in mice.;Sumer 3;2023-10-15